Our work on Cognitive Impairment centers on early detection and intervention against diseases that lead to dementia, with a primary focus on early predictors of dementia and Alzheimer’s disease. These conditions involve irreversible processes that develop insidiously over 10-20 years before clinical symptoms appear, making early precise disease diagnosis crucial. To identify early predictors and disease markers with dementia as the endpoint, we conduct longitudinal studies involving large cohorts of patients and controls at increased risk of developing dementia. We employ and publish on a wide range of techniques, contributing to advancements in cognitive investigations, imaging, proteomics, and genetics. Our approach involves both publishing major research findings in academic journals and filing key biomarker discoveries as DOFIs (to Inven2) for potential future patents. Currently, these patents have been licensed and commercialized by a biotech startup, Pre Diagnostic.